Royalty Pharma

company

About

Industry leader in investing in marketed and late stage biopharmaceutical products

  • 51 - 100

Details

Industries
Biotechnology,Manufacturing,Pharmaceutical
Founded date
Jan 1, 1996
Number Of Employee
51 - 100
Operating Status
Active

Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research institutions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in forty four approved and marketed biopharmaceutical products and seven products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA”).

Investments

Number of Investments
Number of Lead Investments
1
1
Royalty Pharma has made 1 investments. Their most recent investment was on Jul 1, 2022, when Cytokinetics raised $450M.
Date Company Name
Round Money Raised Industry Lead Investor
Jul 1, 2022 Cytokinetics
Post-IPO Debt $450M Biopharma Yes